Vedolizumab

Therapeutic Vedolizumab antibody from the original Entyvio® commercial drug

Showing the single result

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price
alpha 4 beta 7 integrin
Monoclonal Antibody
Entyvio®
158,8 mg/mL
4 mg
-80°C
12/2021
394,00 
view product
Max: 10
Min: 1
Step: 1

Not looking for Vedolizumab?

Search our therapeutic molecules product database

Entyvio® / Vedolizumab

Drug nameEntyvio®
INNVedolizumab
API typeVedolizumab is a humanised IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic groupImmunosuppressants, selective immunosuppressants
ATC codeL04AA33
Target of antibodyα4β7 integrin
General functionVedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Entyvio is also indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Vedolizumab is a gut-selective immunosuppressive biologic. It is a humanised monoclonal antibody that binds specifically to the α4β7 integrin, which is preferentially expressed on gut homing T helper lymphocytes. By binding to α4β7 on certain lymphocytes, vedolizumab inhibits adhesion of these cells to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), but not to vascular cell adhesion molecule-1 (VCAM-1). MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to tissues within the gastrointestinal tract. Vedolizumab does not bind to, nor inhibit function of, the α4β1 and αEβ7 integrins.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The single and multiple dose pharmacokinetics of vedolizumab have been studied in healthy subjects
and in patients with moderate to severely active ulcerative colitis or Crohn’s disease
Original license holder
Marketing authorisation numbersEU/1/14/923/002
Marketing authorisation holderTakeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand Denmark
Name of the manufacturer of the biological active substanceAbbVie Bioresearch Center 100 Research Drive Worcester, MA 01605-4314 USA; Abbvie Biotechnology, Ltd Road #2 Km 59.2 PO Box 2191 Barceloneta Puerto Rico 00617; Lonza Biologics, Inc. 101 International Drive Portsmouth NH 03801 USA
Name and address of the manufacturer(s) responsible for batch releaseDelpharm Novara S.r.l. Via Crosa, 86 28065 Cerano (NO) Italy; Takeda Austria GmbH St. Peter-Straße 25 4020 Linz Austria
Max shelf life24 months
Storage conditions2 °C-8 °C
List of excipientsCitric acid monohydrate - Sodium citrate dihydrate - L-histidine - L-histidine monohydrochloride - L-arginine hydrochloride - Polysorbate 80 - Water for injections
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.